Adaptimmune Therapeutics
ADAPAdaptimmune is a UK-based biotech focused on developing novel TCR T-cell therapies for cancer. The company recently underwent significant strategic changes, including the sale of its TECELRA, lete-cel, afami-cel, and uza-cel programs to US WorldMeds, delisting from Nasdaq, and a leadership overhaul. Its current strategy centers on advancing its earlier-stage PRAME and CD70-targeting programs while reducing operational costs as a private entity.
AI Company Overview
Adaptimmune is a UK-based biotech focused on developing novel TCR T-cell therapies for cancer. The company recently underwent significant strategic changes, including the sale of its TECELRA, lete-cel, afami-cel, and uza-cel programs to US WorldMeds, delisting from Nasdaq, and a leadership overhaul. Its current strategy centers on advancing its earlier-stage PRAME and CD70-targeting programs while reducing operational costs as a private entity.
Technology Platform
Proprietary T-cell receptor (TCR) engineering platform that affinity-enhances TCRs to target intracellular cancer peptides presented on the HLA complex, primarily for the treatment of solid tumors.
Pipeline
8| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Treatment with NY-ESO-1c259-modified T cells | Multiple Myeloma | Phase 1/2 | |
| NYESO-1c259 T cells | Ovarian Cancer | Phase 1/2 | |
| GSK3901961 + GSK3845097 + GSK4427296 + Cyclophosphamide + Fl... | Neoplasms | Phase 1 | |
| WT-gag-TCR modified T cells + α/6-gag-TCR modified T cells | HIV Infections | Phase 1 | |
| Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T | Non-Small Cell Lung Cancer | Phase 1 |
Funding History
4Opportunities
Risk Factors
Competitive Landscape
Competes in the rapidly advancing field of TCR and solid tumor cell therapies against companies like Immunocore, Immatics, and large pharma. Differentiation hinges on the unique target selection (PRAME, CD70) and the proprietary affinity engineering of its TCR platform, but it lags behind leaders in clinical development.